The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions
- Authors
- Lee, Kyoungmin; Song, Joon Seon; Kim, Jeong Eun; Kim, Wanlim; Song, Si Yeol; Lee, Min Hee; Chung, Hye Won; Cho, Kyung-Ja; Lee, Jong-Seok; Ahn, Jin-Hee
- Issue Date
- Jul-2020
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Undifferentiated pleomorphic sarcoma; Prognosis; Adjuvant treatment; PD-L1 expression
- Citation
- European Journal of Surgical Oncology, v.46, no.7, pp 1287 - 1293
- Pages
- 7
- Indexed
- SCIE
SCOPUS
- Journal Title
- European Journal of Surgical Oncology
- Volume
- 46
- Number
- 7
- Start Page
- 1287
- End Page
- 1293
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/28067
- DOI
- 10.1016/j.ejso.2020.02.029
- ISSN
- 0748-7983
1532-2157
- Abstract
- Introduction: Little is known about undifferentiated pleomorphic sarcoma (UPS) because of the low incidence and heterogeneous diagnosis of sarcoma. We investigated the oncologic outcomes of patients with UPS in a real-practice setting in association with adjuvant treatments and assessment of PD-L1 expression. Materials and methods: We retrospectively reviewed consecutive patients who were diagnosed with UPS in Asan Medical Center between January 1995 and December 2016. PD-L1 staining was performed using formalin-fixed paraffin-embedded tumour tissue by immunohistochemistry, and positive PD-L1 expression was defined as staining in >= 1% of tumour cells. The PD-L1 H-score, which was calculated for statistical analysis as intensity (0-3) multiplied by proportion (0-100), ranged from 0 to 300. Results: Of 205 patients included in our analysis, 176 underwent a curative-intent operation for localised disease. The five-year disease-free survival (DFS) rate of resected UPS patients was 54.3%. Administration of adjuvant therapy did not overcome the poor prognostic factors such as primary tumour size (>5 cm) and locations, especially the abdomen and pelvis. The PD-L1 analysis was available for 114 patients, and 83 (72.8%) showed immunoreactivity for PD-L1 with weak (44/83), intermediate (29/83), and strong (10/83) staining intensities. The positive PD-L1 expression seemed to be associated with prolonged DFS, though no statistical significance was observed. Conclusion: Complete surgical resection was the most important UPS treatment strategy, and adjuvant radio- or chemotherapy was insufficient to improve survival. Our results raise the possibility that immunotherapy could be a breakthrough in the treatment of UPS patients. (C) 2020 Elsevier Ltd, BASO - The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.